Clinical Trial

Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.
Trial Details
NCT Number NCT07364656
Lead Sponsor IRCCS Policlinico S. Donato
Collaborators: IRCCS San Raffaele
Conditions Brugada Syndrome (BrS), Breast Cancer Females, Colon Cancer, ECG Abnormalities, Autoantibodies Screening
Enrollment 196 participants
Start Date 2026-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-23